Arax Advisory Partners’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Arax Advisory Partners’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$997K	Buy	10,068 +9,513	+1,714%	+$857K	0.01%	1218
2026 Q1	$48.1K	Buy	555 +531	+2,213%	+$46.5K	﹤0.01%	1710
2025 Q4	$2.04K	Buy	+24	New	+$1.92K	﹤0.01%	3254

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Arax Advisory Partners's IHE Position: Q2 2026 in Review

Arax Advisory Partners increased its iShares US Pharmaceuticals ETF (IHE) stake by 1,714% in Q2 2026, buying an estimated $857K and bringing the position to 10,068 shares worth $997K. The position accounts for 0.01% of the portfolio, ranked #1218.

Arax Advisory Partners first reported a position in IHE in Q4 2025 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Arax Advisory Partners held 10,068 shares of iShares US Pharmaceuticals ETF worth $997K as of Q2 2026.
Arax Advisory Partners bought 9,513 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $857K.
iShares US Pharmaceuticals ETF made up 0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1218 holding.
Arax Advisory Partners first reported a position in iShares US Pharmaceuticals ETF in Q4 2025 and has held it in 3 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.